Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study.

ABSTRACT:

Background

Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces renal risks in type 2 diabetic nephropathy, but its use in immunoglobulin nephropathy (IgAN) lacks evidence. This study assessed the safety and efficacy of 6-month finerenone treatment in IgAN patients.

Methods

This retrospective cohort study was mainly conducted in three Grade 3A hospitals. Patients diagnosed with IgAN and receiving standard supportive care were included. Participants were divided into the renin-angiotensin system inhibitor (RASI) and RASI + finerenone groups. The primary outcome was the percentage decrease in protein-to-creatinine ratio (PCR) over 6 months following the index study visit.

Results

In total, 178 patients were included in the analysis. PCR was reduced

SUBMITTER: Wang QR 

PROVIDER: S-EPMC12067071 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature